Fampyra making headlines

**UPDATE**

MS Ireland
30 Oct 2014

The HSE have confirmed that negotiations are still underway regarding Fampyra. No decision about reimbursement has yet been reached.

The Irish Times is today reporting that the HSE has rejected a second application from Biogen Idec, the manufacturers of Fampyra, to have it covered under State-funded drug schemes. However MS Ireland has received no confirmation on this. We are actively engaging with all parties concerned to seek clarification and will provide an update as soon as possible.

Fampyra made headlines earlier this year when it was revealed that people who were receiving Fampyra for free on a named-patient basis would, as of 1st July 2014, be faced to pay up to €500 per month to continue the treatment.

MS Ireland has been advocating on behalf of people with MS on this issue and encouraging people to actively engage with their local politicians to ensure access to treatments remains on the government's agenda. We again stress this call and ask that people with MS take action and lobby their local TD now to ensure their voices are heard on this important issue.

Related